In further support of this conclusion, the CDK2 inhibitor SNS-032 inhibited the activity of SARS-CoV-2 RdRp with an EC50 of 73 nM (Fig. 6b), as opposed to the CDK1 inhibitor Ro-3306 exhibiting no significant effect on Gluc expression up to 7 μM (Fig. 6b), which is more than 600-fold higher than the reported IC50 110 nM against CDK1.28 Finally, we evaluated the antiviral activity of SNS-032 against SARS-CoV-2 (MOI of 0.05) by infecting Vero cells and measuring viral infection by quantifying viral genomic RNA with RT-qPCR. This evidence concerns the gene CDK2 and viral infectious disease.